Genmab wins biotechnology's Helix Award 2004
Genmab was honored for its significant advances during 2004 that included the presentation of positive data from all five of its clinical programs: Phase II proof of concept data for two products, HuMax-CD4 and the Amgen partnered AMG-714, and promising Phase I/II data for HuMax-CD20, HuMax-EGFr and HuMax-Inflam. Genmab also received Fast Track designations for HuMax-CD4 and HuMax-CD20 from the FDA and obtained two Orphan Drug designations. In the financial area, the company raised a total of approximately DKK 542 million (approximately US$100 million), primarily through a successful follow on offering, and the company's stock price appreciated by 96% during the year.
The award was presented by the Long Island Life Sciences Initiative and is jointly sponsored by the Biotechnology Industry Organization, Stony Brook University and The Center for Biotechnology.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.